Mutation

(redirected from Gain of function)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia.

MUTATION, French law. This term is synonymous with change, and is particularly applied to designate the change which takes place in the property of a thing in its transmission from one person to another; permutation therefore happens when, the owner of the thing sells, exchanges or gives it. It is nearly synonymous with transfer. (q.v.) Merl. Repert. h.t.

A Law Dictionary, Adapted to the Constitution and Laws of the United States. By John Bouvier. Published 1856.
References in periodicals archive ?
While increased high density lipoprotein cholesterol level was found to be associated with 36% lower risk of obesity.4 LPL gene rs328 (S447X) polymorphism is reported as gain of function by many investigators.
The mutation was present with a frequency of 25% within the sample, representing a somatic gain of function mutation.
"What we know is that if you have a gain of function mutation in CARD 14, we think that this activates the NFkB pathway and leads to increased inflammation of the skin.
HIROSHIMA, Japan, June 8, 2017 - A clinical study testing the response of 15 patients with a "gain of function" mutation of the STAT1 gene to stem cell transplantation found that only five were cured - a "disappointing" but encouraging result, according to the researchers.
The authors tested the effects of the drug on action potential properties and conduction velocity in the settings of two Na+ channel gain of function mutations that are correlated with hyperexcitability and ectopic premature contractions.
Among these diseases, APECED, ALPS, IPEX, IPEX-like syndromes (CD25 and STAT5b deficiency, LRBA deficiency, CTLA4 deficiency, gain of function mutation of the STAT1 gene), IL-10/IL-10 receptor deficiency and newly defined Phospholipase C-gamma-2-related autoantibody deficiency and immune dysregulation (PLAID) are characterized by autoimmunity.
Genetic mutations in sodium channels result in a gain of function or loss of function with a concomitant change in sensitivity to painful stimuli.
CYP2C19 loss of function (LOF) and gain of function (GOF) genotype, adenosine 5′-diphosphate (ADP)-channel platelet inhibition rate (PIR) tested by TEG and the occurrence of 3-month major adverse cardiovascular events and ischemic events were assessed in 116 patients.
In addition, it has been shown that mutant p53 proteins are able to inhibit WT TP53 through dominant negative gain of function. Different mutated p53 proteins may inhibit DNA damage response, cell cycle control and apoptosis process induced by the WT one.